Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions of novel triazine compounds

a triazine compound and compound technology, applied in the field of triazine compounds, can solve the problems of chronic inflammation leading to complications and ongoing system damage, endothelial damage, vascular complications,

Inactive Publication Date: 2007-01-04
REDDY US THERAPEUTICS
View PDF23 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While inflammation in and of itself is a normal immune response, chronic inflammation leads to complications and ongoing system damage due to the interactions of unknown cellular factors.
In particular, chronic inflammation can cause endothelial damage resulting in vascular complications.
Many humans and animals have limited lifespans and lifestyles because of conditions relating to lifestyle choices, such as diet and exercise, or because of genetic predispositions to develop a disease.
Currently there are no effective pharmacological treatments available that control the pathogenesis of vascular occlusive lesions, such as, but not limited to, arteriosclerosis, atherosclerosis, restenosis, and graft atherosclerosis after organ transplantation.
There is a present need for treatments of chronic or acute diseases, such as atherosclerosis, unwanted cellular growth or cellular proliferation, diabetes, inflammatory conditions and vascular occlusive pathologic conditions, because occurrence is frequent, the currently available treatments are costly and the conditions are refractory to many pharmacological therapies.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions of novel triazine compounds
  • Methods and compositions of novel triazine compounds
  • Methods and compositions of novel triazine compounds

Examples

Experimental program
Comparison scheme
Effect test

example 1

General Synthetic, Purification, Characterization, and Spectroscopic Procedures

[0572] General Synthetic Procedures. Room temperature is defined as an ambient temperature range, typically 20-25° C. An ice bath (crushed ice / water) temperature is defined as a range, typically −5 to 0° C. Temperature at reflux is defined as +15° C. of the boiling point of the primary reaction solvent. Overnight is defined as a time range of 8-16 hours. Vacuum filtration (water aspirator) is defined as range of 5-15 mm Hg. Dried under vacuum is defined as using a high vacuum pump as a range of 0.1-5 mm Hg. Neutralization is defined as a typical acid-based neutralization method and measured to a pH 6-8 range using pH-indicating paper. Brine is defined as a saturated aqueous sodium chloride. Nitrogen atmosphere is defined as positive static pressure of nitrogen gas passed through a Drierite column with an oil bubbler system. Concentrated ammonium hydroxide is defined as an approximately 15 M solution.

[05...

example 2

General Methods for Parallel Synthesis

[0585] Examples 3-5 describe the synthetic procedures for the preparation of the “library” of N2,N4,N6-tris(amino)-1,3,5-triazines which was prepared based on the strategy of changing only one pendant amino group per synthesis, and based on the parent structure 95 shown below, where each compound in the library contains two of the pendant groups in 95.

[0586] The library was divided into three subgroups, and all three subgroups are presented in Table 2. Library 1 (compounds 1-50) includes compounds having unchanged cycloheptylamino and [(1-ethyl-2-pyrrolidinyl)methyl]amino substituents, with various groups being permuted at the remaining triazine amino position, prepared by Method A as presented in Example 3. Library II (compounds 51-75) includes compounds having unchanged [(1-ethyl-2-pyrrolidinyl)methyl]amino and (3-fluoro-4-methoxyphenyl)amino substituents, with various groups being permuted at the remaining triazine amino position, prepared...

example 3

Parallel Synthetic Method A, for Library I Compounds

[0587] The following reaction scheme presents the general reagents and conditions for parallel synthetic method A used for the compounds of Table 2 which designate Method A.

[0588] A stock solution of cyanuric chloride (0.542 M) in 1,4-dioxane was prepared and 1 mL of this solution (containing 100 mg or 0.542 mmol) was dispensed into each of 50 barcoded 40 mL vials. These solutions were cooled to about −11° C. (freezing) using a J-KEM block connected to a circulating cooler. Meanwhile, individual solutions of each aryl amine ArNHR (specified as Monomer 1 in Table 2, 0.542 mmol) and disopropylethylamine (DIEA) (77 mg / 104 μL, 0.596 mmol) in 1 mL of CH3CN were prepared. (For HCl salts, 204 μL DIEA (approx. 2.1 equiv) was used.) Over a period of about 1 h, the amine / DIEA solutions were added to the corresponding frozen cyanuric chloride solutions, one by one, with swirling. The resulting solutions were then shaken at about −11° C. fo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pharmaceutical compositionaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Description

PRIOR RELATED U.S. APPLICATION DATA [0001] This application is a continuation application of co-pending U.S. patent application Ser. No. 10 / 397,968, filed Mar. 26, 2003, which is a continuation-in-part of U.S. patent application Ser. No. 10 / 390,485 filed Mar. 17, 2003, which is a continuation of U.S. patent application Ser. No. 10 / 253,388, filed Sep. 23, 2002, which claims priority to U.S. Provisional Application Ser. No. 60 / 324,147 filed Sep. 21, 2001, each of which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention relates to triazine compounds. More particularly, the invention relates to methods and compositions for making and using triazine compounds. BACKGROUND OF THE INVENTION [0003] Synthesis of novel compounds leads to new possibilities for discovery of novel therapeutic interventions. By using structure and activity relationship investigations, compounds can be tailored so that the compounds have at least one activity tha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/53C07D403/02C07D251/54C07D251/44C07D251/46C07D251/48C07D251/50C07D251/52C07D251/66C07D251/70C07D401/04C07D401/12C07D401/14C07D403/04C07D403/12C07D403/14C07D405/12C07D405/14C07D409/12C07D409/14C07D413/14C07D417/04C07D417/12C07D417/14C07D453/02C07D487/04C07F9/6521C07F9/6558
CPCA61K31/53C04B35/632C07D251/30C07D251/44C07D251/46C07D251/48C07D251/50C07D251/52C07D251/66C07D251/70C07D401/04C07D401/12C07D401/14C07D403/04C07D403/12C07D403/14C07D405/12C07D405/14C07D409/12C07D409/14C07D413/04C07D413/14C07D417/04C07D417/12C07D417/14C07D453/02C07D487/04C07F9/65583C07F9/6521
Inventor TIMMER, RICHARDALEXANDER, CHRISTOPHERPILLARISETTI, SIVARAMSAXENA, UDAYYELESWARAPU, KOTESWARPAL, MANOJITREDDY, JANGALGARREDDY, VELAGALA VENKATA RAMAALLURI, SESHAKUMAR, POTLAPALLYREDDY, GADDAM
Owner REDDY US THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com